Results 301 to 310 of about 258,738 (344)
Some of the next articles are maybe not open access.
Combined Modality Therapy for Rectal Cancer
The Cancer Journal, 2016The primary therapy for any potentially curative rectal cancer is surgery. For locally advanced tumors (i.e., T3-4 and/or node positive), the very high rate of local and distant recurrences has necessitated a standard adjuvant regimen of preoperative chemoradiation and postoperative chemotherapy.
Sagar A. Patel +2 more
openaire +3 more sources
Combined modality therapy of malignant melanoma
World Journal of Surgery, 1979AbstractThe major modalities of therapy, namely, surgery, radiotherapy, chemotherapy, and immunotherapy, are each of value in selected cases of malignant melanoma. However, because none of these therapies, alone, is capable of curing or controlling some subgroups of melanoma patients, combined modality therapy needs to be used more extensively. Surgery
Evan M. Hersh +2 more
openaire +3 more sources
Combined Modality Therapy of Esophageal Cancer
Journal of the National Comprehensive Cancer Network, 2008Esophageal cancer is a deadly disease. Only one third of patients with localized disease experience long-term survival. Over the past 20 years, investigators have evaluated neoadjuvant strategies to improve the outcomes of surgical management. Chemotherapy and radiation have been evaluated individually and in combination for preoperative management of ...
Arlene A. Forastiere +1 more
openaire +2 more sources
Combined modality therapy: Is it necessary for everyone?
Seminars in Colon and Rectal Surgery, 2013Abstract Survival and relapse in rectal cancer are intimately associated with disease stage. Although surgery remains the primary treatment modality for rectal cancer, its limitations as an isolated curative treatment are well recognized. Trimodality therapy combining surgery, chemotherapy, and radiation has improved local recurrence rates and ...
Matthew R. Porembka, Martin R. Weiser
openaire +2 more sources
Combined modality therapy for esophageal cancer
Seminars in Oncology, 2003Treatment approaches for esophageal cancer include primary treatment (surgical or nonsurgical) or adjuvant treatment (preoperative or postoperative). Primary treatments include surgery alone, radiation therapy alone, and radiation therapy plus chemotherapy (combined modality therapy).
openaire +3 more sources
The Role of Gemcitabine in Combined Modality Therapy
2003Gemcitabine is a novel pyrimidine nucleoside analog with a broad spectrum of clinical antitumor activity. In addition to its initial approved indication in pancreatic carcinoma, gemcitabine has been licensed for the treatment of nonsmall-cell lung cancer (NSCLC) (1).
William Blackstock +4 more
openaire +2 more sources
Preoperative combined modality therapy for pancreatic cancer
World Journal of Surgery, 1995AbstractCombined modality therapy can be administered prior to surgical resection for patients with operable pancreatic cancer. One important criteria used to select patients for this treatment sequence is the absence of arterial vascular encasement by tumor on thin‐section CT scanning; the absence of peritoneal seeding on surgical staging or ...
Douglas B. Evans, Tvvin A. Rich
openaire +3 more sources
Combined modality therapy in the treatment of gynecologic malignancies
Seminars in Oncology, 2003During the last several years, combined modality therapy has become increasingly important in the treatment of several malignancies. This trend holds true in the treatment of the gynecologic malignancies. In this review we examine the evolving role of combined modality therapy in the treatment of patients with cervical, vulvar, endometrial, and ovarian
Mark A. Engleman, William Small
openaire +3 more sources
Combined modality therapy for esophageal cancer
Seminars in Radiation Oncology, 1997Esophageal cancer remains one of the deadliest gastrointestinal malignancies. Single modality therapy for esophageal cancer usually consists of surgery or radiation therapy. Despite wide ranges in survival rates reported for the two modalities, recent analyses suggest that each offers a 5-year survival of approximately 6%.
Hak Choy +2 more
openaire +2 more sources
Taxanes in combined modality therapy for solid tumors
Critical Reviews in Oncology/Hematology, 2001The taxanes, paclitaxel and docetaxel, are novel antimitotic agents that are under extensive investigation in clinical trials. Both taxanes have demonstrated significant activity against many solid tumors as single agents and in combination with other chemotherapeutic agents.
openaire +4 more sources